Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
04:11pm, Tuesday, 17'th Feb 2026
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital–
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of “Hold” by Analysts
03:19am, Monday, 16'th Feb 2026
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are covering the firm, MarketBeat Ratings reports.
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
09:18pm, Thursday, 12'th Feb 2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving Average – What’s Next?
03:18am, Saturday, 31'st Jan 2026
Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.38
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:16pm, Tuesday, 13'th Jan 2026
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200 Day Moving Average – Should You Sell?
03:06am, Friday, 09'th Jan 2026
Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) crossed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $1.26 and traded
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
09:30am, Tuesday, 06'th Jan 2026
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference o
-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
11:06am, Tuesday, 23'rd Dec 2025
Coherus Oncology maintains a 'Buy' rating, driven by a promising clinical pipeline and undervaluation relative to cash and equity holdings. CHRS's commercial growth is anchored by toripalimab sales in
-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - -6 Years
Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript
05:01pm, Monday, 10'th Nov 2025
Coherus Oncology, Inc. ( CHRS ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development
Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript
05:56pm, Friday, 07'th Nov 2025
Coherus Oncology, Inc. ( CHRS ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairm
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
09:00am, Friday, 07'th Nov 2025
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
09:16pm, Thursday, 06'th Nov 2025
Coherus Oncology (CHRS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.01 per share a year ago.
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
04:14pm, Thursday, 06'th Nov 2025
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – –
